oxybutynin has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 2 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rasagiline mesylate is used as first line agent for early management of Parkinson's disease but its water soluble nature creates hurdles to cross blood brain barrier also its low oral bioavailability and rapid elimination requires frequent dosing." | 1.56 | Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism. ( Bali, NR; Salve, PS, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bali, NR | 1 |
| Salve, PS | 1 |
| Moretti, DV | 1 |
| Binetti, G | 1 |
| Zanetti, O | 1 |
| Frisoni, GB | 1 |
1 trial available for oxybutynin and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Dopamine Agonists; Follow-Up Studies; Humans; | 2014 |
1 other study available for oxybutynin and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Behavior, Animal; Brain; Catalepsy; Diffus | 2020 |